News

Business Wire7y
WindMIL Therapeutics Announces $32.5 Million in Series B Financing
BALTIMORE--(BUSINESS WIRE)--WindMIL Therapeutics, a clinical stage company developing Marrow-Infiltrating Lymphocytes (MILs™) for cancer immunotherapy, today announced the completion of a $32.5 ...
Business Insider5y
WindMIL Therapeutics Announces Dosing of First Patient in a Phase 2a Clinical Trial of Marrow-Infiltrating Lymphocytes (MILs™) for Treatment of Patients ... - Markets Insider
BALTIMORE and PHILADELPHIA, Dec. 12, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, today ...
Yahoo Finance4y
WindMIL Therapeutics Presents New Marrow-Infiltrating Lymphocytes (MILs®) Data Demonstrating Broad Therapeutic Promise for Solid Tumor Cancers - Yahoo Finance
PHILADELPHIA and BALTIMORE, Nov. 09, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs®) products for cancer immunotherapy ...
Business Insider4y
WindMIL Therapeutics and Stephenson Cancer Center Announce Collaboration to Collect Bone Marrow from Patients with Renal and Urothelial Carcinomas to Develop Marrow ...
PHILADELPHIA, BALTIMORE and OKLAHOMA CITY, Oct. 13, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics (WindMIL) and Stephenson Cancer Center today a ...
Technical7y
WindMIL Therapeutics raises $32.5 million - Technical.ly
WindMIL Therapeutics, a Baltimore-based company specializing in cell therapy to treat cancer, closed on $32.5 million in Series B funding, the company announced on Monday. The round was led by Qiming ...
Technical6y
JHU spinout WindMIL Therapeutics expands to Philly, adds two new executives
WindMIL drew attention in June, when it closed a $32.5 million funding round. Along with the new location, the company is based in Johns Hopkins FastForward 1812, where its science team utilizes the ...
The Business Journals6y
Baltimore-based WindMil Therapeutics opens Philadelphia office - Philadelphia Business Journal
WindMil Therapeutics, a clinical-stage cancer immunotherapy company based in Baltimore, has opened a Philadelphia office to accommodate its expanding executive, operations and clinical teams.
Yahoo Finance4y
WindMIL Therapeutics to Present at Citi's 15th Annual BioPharma Virtual Conference - Yahoo Finance
PHILADELPHIA and BALTIMORE, Sept. 03, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs™) products for cancer immunotherapy ...
MM&M4y
WindMil Therapeutics adds to cofounder’s role
WildMil Therapeutics announced that cofounder Kimberly Noonan, Ph.D, MPH, has been named EVP, chief science and technology officer. “It’s an exciting time at WindMil, with the ongoing enrollment of ...
Nasdaq5y
WindMIL Therapeutics Announces Dosing of First Patient in Phase 2 Clinical Study of MILs™ - NSCLC in Combination with Nivolumab (Opdivo®) for the Treatment of Non ... - Nasdaq
PHILADELPHIA and BALTIMORE, May 28, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs™) products for cancer immunotherapy ...
Wall Street Journal7y
Immuno-Oncology Company WindMIL Therapeutics Closes $32.5 Million Series B - WSJ - The Wall Street Journal
WindMIL Therapeutics, a Baltimore-based cancer immunotherapy startup, has completed a $32.5 million Series B round led by Qiming Venture Partners USA.